Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 3
Recruiting
- Conditions
- Vulvar CancerCIN1CIN3VaIN1Genital WartAISVaginal CancerVaIN3Cervical CancerVaIN2
- Interventions
- Biological: GARDASIL®Biological: 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 8000
- Registration Number
- NCT04422366
- Locations
- 🇨🇳
Liuzhou center for disease control and prevention, Liuzhou, Guangxi, China
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 1
Completed
- Conditions
- Vulvar CancerGenital WartCIN2AISVin IIICIN1VaIN3Vaginal CancerCIN 3Invasive Carcinoma
- Interventions
- Biological: PlaceboBiological: 9-valent HPV Recombinant Vaccine
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT03676101
- Locations
- 🇨🇳
Zhejiang Provincial Center for Disease Control and Prevention, Hanzhou, China
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
Phase 1
Completed
- Conditions
- HPV Infections
- Interventions
- Biological: PlaceboBiological: HPV vaccine
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT03085381
- Locations
- 🇨🇳
Liu Zhou Centre for Disease Control and Prevention, Liuzhou, Guangxi, China
© Copyright 2025. All Rights Reserved by MedPath